
CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 10**

PHARMACY BENEFITS MANAGEMENT SERVICES**TABLE OF CONTENTS**

SUBJECT

SECTIONS

OVERVIEW **37.0***Providers should refer to Chapter 1 – General Information and Administration of the Medicaid Services Manual for additional information.***COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS** **37.1**

Terms and Conditions

Tamper-Resistant Prescription Policy

Authorized Benefits

Non-Covered Services

Prior Authorization and Single Preferred Drug List (PDL)

Clinical Authorization

Monthly Service Limit

Limit

Exceptions to Limit

Limit Override Procedures

Drugs with Special Payment Criteria/Limitations

Age and Gender Restricted Drugs

Acne Agents

Agalsidase Beta (Fabrazyme®)

Alglucosidase (Lumizyme®)

Allergen Extracts

Anti-Anxiety Drugs

Analeptics: Armodafinil (Nuvigil®) and Modafinil (Provigil®)

Anticoagulants

Antihistamine/Decongestant Products

Antisense Oligonucleotides: Nusinersen sodium (Spinraza) and Telisen
(Exondys 51®)

Androgenic Agents (Testosterone and Methyltestosterone containing products)

Antipsychotic Agents

Diagnosis Code Requirement on All Antipsychotic Medications

Age and Dosage Limits

Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD)

CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 10**

Agents

Therapeutic Duplication

Behavioral Health Medications for Beneficiaries Less than 6 Years of Age

Clinical Pre-Authorization for ADHD Medications for Beneficiaries Less Than 48 Months

Buprenorphine and Buprenorphine/Naloxone Agents (Bunavail, Suboxone®, and Zubsolv®)

Diagnosis Code Requirement

Quantity Limits on Buprenorphine-Naloxone Products

Concurrent Opioid Analgesic and/or Benzodiazepine Therapies

Buprenorphine Buccal Film (Belbuca®)

Buprenorphine Extended-Release Injection (Sublocade®)

Buprenorphine Implant Kit (Probuphine®)

Buprenorphine Transdermal Patches (Butrans®)

Cariprazine (Vraylar®) and Cariprazine (Vraylar®) Therapy Pack

Carisoprodol

Codiene

Contraceptive Agents

Drospirenone/Ethinyl Estradiol/Levomefolate Calcium (Beyaz®)

Etonogestrel (Nexplanon®)

Etonogestrel/Ethinyl Estradiol Vaginal Ring (Nuvaring®)

Oral Contraceptive Agents

Medroxyprogesterone/Acetate Injectable

Norelgestromin/Ethinyl Estradiol/Transdermal Patches (Ortho-Evra®)

Cytokine and Cell-Adhesion Molecule (CAM) Antagonists

Deferasirox (Exjade®)

Beneficiaries 2 years of age and less

Beneficiaries 2-9 years of age

Beneficiaries 10 years of age and older

Diabetic Testing Supplies

Eculizumab (Soliris®)

Epinephrine Injection (Generic, EpiPen®, and EpiPen Jr.®)

Fertility Agents

Granulocyte Colony Stimulating Factor Agents (GCSF)

Growth Hormone

Hepatitis C Virus Direct-Acting (DAA) Antiviral Agents

Hydroxyprogesterone Caproate (Makena®)

Isotretinoin

Ivacaftor (Kalydeco®)

CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 10**

Ketorolac	
Linezolid (Zyvox®)	
Lipotropics: Lonitapide (Juxtapid®), Mipomersen (Kynamro®), Alirocumab (Praluent®, and Evolocumab (Repatha ®)	
Lumacaftor/Ivacaftor (Okambi®)	
Mnocolonal Antibodies (Respiratory): Benralizumab Injection (Fasenra®, Mepolizumab Injection (Nucala®, Omalizumab (Xolair), and Reslizumab	
Pimavanserin (Nuplazid®)	
Mosquito Repellents	
Quantity Limits	
Age Restriction	
Multiple Sclerosis (MS) Treatment Agents	
Naloxone	
Nicotine Transdermal Patches, Gum and Spray	
Orlistat	
Palivizumab (Synagis®)	
Respiratory Syncytial Virus Season	
Age Restriction	
Early Refill	
Maximum Number of Doses Allowed	
Medical Reconsideration for Palivizumab (Synagis®)	
Palivizumab Criteria ICD-10_CM Code and Medication List	
Neuromuscular Disorders	
Congenital Abnormalities of the Airways	
Chronic Lung Disease	
Congenital Heart Diseases (CHD)	
Schedule II Narcotic Agents	
Fentanyl Buccal, Nasal, and Sublingual Agents	
Diagnosis Code Requirement	
Age Restriction	
Methadone	
Morphine ER (Avinza®)	
Oxycodone/Acetaminophen 7.5/325mg (Xartemis XR®)	
Paroxetine Mesylate (Brisdelle®)	
Perampanel (Fycompa ®)	
Roflumilast (Daliresp®)	
Short Acting Beta ₂ Agonist Inhalers	
Diagnosis Code Requirement	
Quantity Limit	

CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 10**

Therapeutic Duplication	
Sildenafil (Revatio®) and Tadalafil (Adcirca®)	
Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combination Products	
Sodium Oxybate (Xyrem®)	
Clinical Pre-authorization	
Therapeutic Duplication	
Somatropin	
Suvorexant (Belsomra®)	
Tasimelteon (Heltioz®)	
Tazarotene (Tazorac®)	
Tedizolid Phosphate (Sivextro®)	
Tezacaftor/Ivacaftor (Symdeko ®)	
Tramadol	
Triptans	
Diagnosis Code Requirement for Selected Medications	
Prospective Drug Utilization Policies/Limits/Edits	
Duration of Therapy Limits	
H ₂ Antagonists and Sucralfate	
Proton Pump Inhibitors (PPIs)	
Early Refill	
Duplicate Drug Therapy	
Pregnancy and FDA Category X Drugs	
Pregnancy and FDA Category D Drugs	
Therapeutic Duplication	
First Generation Antihistamine	
Second Generation Antihistamine	
First Generation Antihistamine-Decongestant	
Second Generation Antihistamine-Decongestant	
Angiotensin Converting Enzyme (ACE) Inhibitors and ACE Inhibitor/Diuretic Combinations	
ACE Inhibitors/Calcium Channel Blocker Combinations	
Angiotensin Receptor Antagonists (ARB) and ARB/Diuretic Combinations	
ARB/Calcium Channel Blocker Combinations	
Beta-Adrenergic Blocking Agents and Beta-Adrenergic Blocking Agent/Diuretic Combinations	
Calcium Channel Blockers	
Calcium Channel Blocker/Antihyperlipemia Agent Combination	
Potassium Replacement	
Tricyclic Antidepressants	

CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 10**

Selective Serotonin Reuptake Inhibitors	
Antipsychotic Agents (Typical and Atypical)	
Antipsychotic/Selective Serotonin Reuptake Inhibitor Combinations	
Anti-Anxiety Agents	
Sedative Hypnotic Agents	
Attention Deficit Disorder (ADD) Agents	
Non-Steroidal Anti-Inflammatory Agents	
Short Acting Beta ₂ Agonist Inhalers	
Short Acting Opiate Agents	
Long Acting Opiate Agents	
Proton Pump Inhibitors	
Drug/Drug Interaction	
Unnecessary Drug Therapy	
Selective Cox-2 Inhibitor	
Maximum Dosage	
Atypical Antipsychotic Agents	
Agents Containing Acetaminophen or Aspirin	
Sedative Hypnotic Agents	
Tapentadol (Nucynta®)	
Agents containing Tramadol	
Botulinum Toxins OnabotulinumtoxinA (Botox®) and IncobotulinumtoxinA (Xeomin®)	
Hydrocodone Containing Agents	
Lidocaine Patches (Lidoderm®)	
Naltrexone Injection (Vivitrol®)	
Opioids	
Serotonin Agents (Tryptans)	
Quantity Limitations	
Maximum Allowable Quantities	
Maintenance Medication Quantities	
Coverage and Limitations for Long Term Care Facility Beneficiaries	
Quantities for Long Term Care Facility Beneficiaries	
Co-payment Exemption	
Over-the-Counter Drugs	
Over-the-Counter Drugs for Preventive Care	
Diabetic Supplies	
Nebulizer Medications	
Medicare Skilled Nursing Facilities	
Emergency Kits	

CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 10**

Outpatient Drugs Covered by Medicare Part B

Drug Services for Hospice Beneficiaries

PROVIDER REQUIREMENTS AND PARTICIPATION GUIDELINES**37.2**

Providers should refer to Chapter 1 - General Information and Administration of the Medicaid Services Manual for additional information on provider enrollment and requirements, including general standards of participation.

Provider Qualifications

Provider Rights and Responsibilities

Record Keeping Requirements

Prohibition of Reassignment of Provider Claims

Out-of-State Providers

Provider Enrollment

Medicaid Durable Medicaid Equipment/Supplies

Medicare Enrollment

Enrollment Process

Point of Sale (POS) Enrollment

Provider Record

Reporting Changes

Reporting the IRS

Louisiana Medicaid Website

Single Preferred Drug List

Clinical Drug Inquiries

Prescriber Numbers

Prior Approval Program

Beneficiary/Recipient Eligibility

Medicaid Eligibility Verification System (MEVS)

Recipient Eligibility Verification System (REVS)

Point of Sale (POS) User Guide

Vendor Specifications Document for the POS System

Drug Appendices

Third Party Liability Carrier Code List

Medicaid Fraud and Abuse

Beneficiary Prescription Verification Letters

Surveillance Utilization Review Subsystem (SURS)

Appeals

Provider Audits

Audit Purpose

CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 10**

Audit Authority
Audit Overview and Process
Provider Responsibilities

REIMBURSEMENT FOR PHARMACY SERVICES**37.3**

Reimbursement Methodology
 National Drug Code (NDC) System
 Maximum Allowable Overhead Cost (Dispensing Fee)
 Provider Fee
Usual and Customary Charges
Drug Estimated Acquisition Cost
Multiple Source Drugs
 Federal Upper Limit (FUL) Regulations
 Louisiana State Maximum Allowable Cost (LMAC) Regulations
 Override of FUL and MAC
Co-payments for Prescription Services
 Co-payment Schedule
 Co-payment Exemptions
 Other Co-payment Policies
Medicare Crossover Claims
Third Party Liability Claims

MANAGED CARE APPLICABILITY**37.4****APPENDIXES****37.5**

37.5.1 – Forms and Links
37.5.2 – Claims Related Information
37.5.3 – Glossary
37.5.4 – Contact Information
37.5.5 – Drug List (PDL) and Non-Preferred Drug List (NPDL)
37.5.6 – Prescribers
 Qualified Prescribers
 Prescriber Numbers

CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 10**

Prescribers Who Are Not Medicaid Program Providers
Sanctioned Providers
Accessing Prescriber Numbers

37.5.7 – Medicare Prescription Drug Coverage

Medicare
Medicare Part B Crossover Claims
General Medicare Part B Crossover Reimbursement Policies
Medicare Part B Outpatient Drug Coverage
 Immunosuppressive Drugs
 Oral Cancer Chemotherapy Drugs
 Antiemetic Drugs
 Nebulizer Drugs
 Diabetic Supplies
 Dispensing/Supply Fees
 Antihemophilia Drugs
Medicare Part D Outpatient Drug Coverage

37.5.8 – Claims Submission and Processing Payments

National Drug Code (NDC)
Drug Quantities and Units of Measurement
Prescriber Numbers
Diagnosis Codes
Overrides
 Federal Upper Limits/Louisiana Maximum Allowable Cost Limitations
 Prescriptions Limit
 Early Refills
 Ingredient Duplication
 Duration of Therapy
 Therapeutic Duplication
 Unnecessary Drug Therapy
 Drug/Drug Interaction
 Coordination of Benefits
 Pregnancy Co-payment
 Age and Gender Overrides
 Maximum Dosage
 Quantity Exceeds Program Maximum
 Prior Authorization (PA) Emergency
 Hospital Discharge Prescriptions for Atypical Antipsychotic Agents

CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 10**

Lock-In Emergency	
Types of Pharmacy Claims	
Point of Sale (POS) Claim Submission (<i>Reference Point of Sale User Guide, Appendix A in this Chapter</i>)	
Electronic Claim Submission (BATCH)	
Hard Copy Claim Submission	
Claim Adjustments	
Time Limit for Submission of Medicaid Claims	
Billing for Spend-Down Medically Needy Beneficiaries	
37.5.9 – Public Health Services 340B Drug Pricing Program	
Reimbursement Methodology	
Covered Entity	
Contract Pharmacies	
37.5.10 – Total Parenteral Nutrition	
Provider Enrollment	
Program Coverage	
TPN Medical Necessity Criteria	
Documentation Requirements	
Exclusionary Criteria	
Intradialytic Parenteral Nutrition Therapy	
Equipment and Supplies	
Prior Authorization	
Prior Authorization Requirements	
Prior Authorization Requests	
Emergency Request	
Medicare Crossover Claims	
Third Party Liability	
Reimbursement Methodology	
Claim Submission	
Medicaid Claims	
Medicare Crossover Claims	
Third Party Liability Claims	
Adjustments/Voids	
37.5.11 – Medication Administration	
Louisiana Board of Pharmacy	
Pharmacist Provider Number	

CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS

PAGE(S) 10

Influenza Vaccine Administration by Pharmacist

37.5.12 – Patient Counseling and Drug Utilization Review (DUR)

Patient Counseling

Prospective Drug Utilization Review (UniDUR)

Retrospective Drug Utilization Review

Drug Utilization Review Board

37.5.13 – Lock-In Program

Choosing a Lock-In Provider

Lock-In Emergencies

Referrals

37.5.14 – Medicaid Drug Rebate Program

Rebate Programs

Federally Mandated Drug Rebate Program

State Supplemental Drug Rebate Program

37.5.15 – Third Party Liability/Coordination of Benefits